Category: FXN Technologies

A gene therapy that delivers a healthy version of the FXN gene can correct heart problems in a new mouse model with cardiac-specific symptoms of Friedreich’s ataxia[2] (FA), a study reports.[1] This animal model more accurately mirrors the early cardiac abnormalities seen in FA patients, the researchers wrote, providing new opportunities to study FA symptoms and investigate disease-modifying therapies. The...

CHICAGO & CAMBRIDGE, Mass.–(BUSINESS WIRE[1])–Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, will host a virtual R&D Day on Thursday, January 7, 2021 from 09:00 am to 10:30 am ET to discuss Exicure’s neuroscience pipeline, including its lead program for Friedreich’s Ataxia (FA). Exicure will discuss its progress with XCUR-FXN,...